Movano (NASDAQ:MOVE) CEO Sells $20,639.94 in Stock

Movano Inc. (NASDAQ:MOVE) CEO John Mastrototaro sold 2,514 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $8.21, for a total value of $20,639.94. Following the transaction, the chief executive officer owned 4,430 shares of the company’s stock, valued at $36,370.30. This trade represents a 36.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Movano Trading Down 3.6%

Shares of NASDAQ MOVE traded down $0.28 during midday trading on Wednesday, hitting $7.50. The company’s stock had a trading volume of 43,178 shares, compared to its average volume of 41,794. The business’s 50 day moving average is $8.73 and its two-hundred day moving average is $7.57. Movano Inc. has a 12-month low of $4.67 and a 12-month high of $59.90. The firm has a market cap of $6.23 million, a P/E ratio of -0.69 and a beta of 0.79.

Movano (NASDAQ:MOVE) last released its earnings results on Friday, November 14th. The technology company reported ($4.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.00) by $2.27. Movano had a negative return on equity of 647.91% and a negative net margin of 3,409.60%.The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $3.88 million.

Hedge Funds Weigh In On Movano

An institutional investor recently bought a new position in Movano stock. Citadel Advisors LLC purchased a new position in Movano Inc. (NASDAQ:MOVE) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 49,262 shares of the technology company’s stock, valued at approximately $28,000. Citadel Advisors LLC owned approximately 5.94% of Movano as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 16.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on MOVE. Wall Street Zen upgraded shares of Movano to a “hold” rating in a research note on Saturday, December 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Movano in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Movano has a consensus rating of “Sell”.

Key Movano News

Here are the key news stories impacting Movano this week:

• Positive Sentiment: Technical upside — Movano’s share price recently moved above its 200‑day moving average, a commonly watched bullish technical signal that can attract momentum traders and short‑covering. Movano Share Price Passes Above 200-Day Moving Average
• Neutral Sentiment: Broader market moods are mixed — major indices swung today (Dow and S&P gave back gains while the Nasdaq was modestly higher), which can mute sector‑specific moves and encourage intraday volatility rather than sustained directional trends. That mixed tape likely limited follow‑through buying in small‑cap names like MOVE. Dow, S&P 500 Give Back Ground But Nasdaq Moves Modestly Higher
• Negative Sentiment: Weak fundamentals and technical resistance — Movano remains a micro‑cap with thin revenue and large reported losses (its last quarterly report showed an EPS beat but revenue far below analyst expectations and very negative margins). The stock still sits below its 50‑day moving average, which can cap rallies and invite selling from traders looking for confirmation. These fundamental/technical negatives increase downside risk and help explain why the stock pulled back after the 200‑day breakout. Movano Stock — MarketBeat Profile

Movano Company Profile

Movano Health, Inc (NASDAQ: MOVE) is a health technology company focused on developing wearable devices for continuous biometric monitoring. The company’s core mission is to provide accessible, real-time health insights through noninvasive sensors, enabling individuals and care teams to track vital signs and physiological trends outside of traditional clinical settings.

Movano’s flagship product is a biometric monitoring ring designed to measure parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality.